| Oct 11 |
VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
|
| Oct 9 |
Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
|
| Oct 9 |
Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
|
| Sep 24 |
Vistagen enrols first subject in Phase III trial of social anxiety disorder drug
|
| Sep 23 |
Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
|
| Sep 6 |
All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
|
| Sep 5 |
Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
|
| Aug 13 |
Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript
|
| Aug 13 |
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
|
| Aug 13 |
VistaGen Therapeutics GAAP EPS of -$0.35 beats by $0.06, revenue of $0.08M misses by $0.22M
|
